Quick Search 
Drug News & Perspectives
Register or sign in

  
 
  
Drug News Perspect 2009, 22(8): 481
ISSN 0214-0934
Copyright 2009 Clarivate Analytics
CCC: 0214-0934
 



FOCUS ON BIOMARKERS

Magnetic resonance imaging biomarkers of ischemic stroke: Criteria for the validation of primary imaging biomarkers

Further large, randomized trials will enable us to overcome the limitations of current MRI biomarkers of acute ischemic stroke and validate new biomarkers

by S. Pedraza, J. Puig, G. Blasco, J. Daunis-i-estadella, I. Boada, A. Bardera, A. Prats, M. Castellanos and J. Serena



Summary

Ischemic stroke is associated with a high rate of disability and death. Establishing valid biomarkers could help accelerate the approval of promising new therapies for stroke. Whereas many serum biomarkers have been evaluated, possible imaging biomarkers of stroke lack validation. Magnetic resonance imaging (MRI) is a very sensitive technique to study acute stroke and MRI parameters have been established to assess the outcome of acute stroke. This review reassesses the criteria for the validation of MRI biomarkers of acute ischemic stroke (MRI-BAS). Seven criteria were used to review the validity of the main MRI-BAS: vascular status, lesion volume, reversibility on diffusion-weighted imaging, perfusion alteration, penumbra studied with diffusion-perfusion mismatch, clinical-diffusion mismatch, diffusion-angiography mismatch and hemorrhagic transformation. We analyzed the definitions of these biomarkers and the extent to which each fulfills the criteria for validation and found that few MRI-BAS have been fully validated. Further studies should help to improve the validation of current MRI-BAS and develop new biomarkers.




Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy